Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy

Conference contribution


Publication Details

Author(s): Bowlus CL, Pockros PJ, Kremer A, Pares A, Forman LM, Drenth JPH, Ryder S, Terracciano L, Floreani A, Jin Y, Lieberman A, Pencek R, Iloeje U, Macconell L, Bedossa P
Publisher: ELSEVIER SCIENCE INC
Publishing place: NEW YORK
Publication year: 2019
Conference Proceedings Title: DIGESTIVE AND LIVER DISEASE
Pages range: E19-E19
ISSN: 1590-8658


FAU Authors / FAU Editors

Kremer, Andreas PD Dr.
Medizinische Klinik 1 - Gastroenterologie, Pneumologie und Endokrinologie


External institutions with authors

Intercept Pharmaceuticals
Nottingham University Hospitals
Radboud University Nijmegen Medical Centre / Radboudumc of voluit Radboud Universitair Medisch Centrum (UMC)
Scripps Research Institute (TSRI)
Universität Basel
Universitat de Barcelona (UB) / University of Barcelona
University of California Davis (UCDAVIS)
University of Colorado System
University of Padua
University of Paris 7 - Denis Diderot / Université Paris VII Denis Diderot


How to cite

APA:
Bowlus, C.L., Pockros, P.J., Kremer, A., Pares, A., Forman, L.M., Drenth, J.P.H.,... Bedossa, P. (2019). Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy. In DIGESTIVE AND LIVER DISEASE (pp. E19-E19). NEW YORK: ELSEVIER SCIENCE INC.

MLA:
Bowlus, C. L., et al. "Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy." Proceedings of the DIGESTIVE AND LIVER DISEASE NEW YORK: ELSEVIER SCIENCE INC, 2019. E19-E19.

BibTeX: 

Last updated on 2019-04-03 at 23:08